CCM
THRD

CAAS Capital Management’s Third Harmonic Bio THRD Stock Holding History

CAAS Capital Management’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,000
Closed -$68.8K – 906
2022
Q4 		$68.8K Hold
16,000
– – ﹤0.01% 675
2022
Q3 		$304K Buy
+16,000
New +$288K 0.01% 586

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAAS Capital Management's THRD Position: Q1 2023 in Review

CAAS Capital Management sold out of Third Harmonic Bio (THRD) in Q1 2023, closing a stake of 16,000 shares — an estimated $68.8K sold.

CAAS Capital Management first reported a position in THRD in Q3 2022 and held it in 2 quarters. The position peaked at $304K in Q3 2022. 49 funds tracked by Wall St. Rank hold THRD as of Q1 2023.

  • CAAS Capital Management reported no remaining Third Harmonic Bio position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 16,000 Third Harmonic Bio shares in Q1 2023, an estimated $68.8K.
  • CAAS Capital Management first reported a position in Third Harmonic Bio in Q3 2022 and held it in 2 quarters.
  • CAAS Capital Management's Third Harmonic Bio position peaked at $304K in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.